Ziqing Ye

Ziqing Ye

Auto-generated profile, based on publicly available information

Ziqing Ye

Department of Gastroenterology, National Children’s Medical Centre, Children’s Hospital of Fudan University , Shanghai

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 May 2018 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
YZYing Zhou
Ying Zhou
ZYZiqing Ye
Ziqing Ye
JHJie Huang
Jie Huang
YHYing Huang
Ying Huang
WYWeili Yan
Weili Yan
YZYi Zhang
Yi Zhang

12 November 2022 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
DADominik Aschenbrenner
Dominik Aschenbrenner
ZYZiqing Ye
Ziqing Ye
YZYing Zhou
Ying Zhou
WHWenhui Hu
Wenhui Hu
IBIsabel Brooks
Isabel Brooks
HUHolm H. Uhlig
Holm H. Uhlig
Balancing natural selection is a process by which genetic variants arise in populations that are beneficial to heterozygous carriers, but pathogenic when homozygous. We systematically investigated the prevalence, structural, and functional consequences of pathogenic IL10RA variants that are associated with monogenic inflammatory bowel disease. We identify 36 non-synonymous and non-sense variants in the IL10RA gene. Since the majority of these IL10RA variants have not been functionally characterized, we performed a systematic screening of their impact on STAT3 phosphorylation upon IL-10 stimulation. Based on the geographic accumulation of confirmed pathogenic IL10RA variants in East Asia and in Northeast China, the distribution of infectious disorders worldwide, and the functional evidence of IL-10 signaling in the pathogenesis, we identify Schistosoma japonicum infection as plausible selection pressure driving variation in IL10RA. Consistent with this is a partially augmented IL-10 response in peripheral blood mononuclear cells from heterozygous variant carriers. A parasite-driven heterozygote advantage through reduced IL-10 signaling has implications for health care utilization in regions with high allele frequencies and potentially indicates pathogen eradication strategies that target IL-10 signaling. Graphical abstract

26 March 2026 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Open access
JXJun Xiao
Jun Xiao
ZYZiqing Ye
Ziqing Ye
YHYing Huang
Ying Huang
Interleukin 10 (IL-10) is a potent anti-inflammatory cytokine. IL-10 receptor (IL-10R) consists of two chains of ligand-binding IL-10RA and two subunits of IL-10RB. IL-10 and IL-10R play important role in maintaining immune homeostasis in the gastrointestinal tract. Mutations in the IL10, IL10R cause spontaneous colitis in mice model and very early onset inflammatory bowel disease (VEOIBD) in human. Patients who have disease onset before 6 years of age are defined as VEOIBD. IL10 and IL10 receptor defect are classified as one type of monogenic inborn errors of immunity (IEI). IL-10 signalling defects demonstrate a Mendelian inheritance pattern with complete penetrance of intestinal inflammation. Patients develop symptoms during infancy and have more severe phenotype than polygenic inflammatory bowel disease (IBD). Here, we review the recent advances in the genetic mechanism, population dynamics and innate and adaptive immune dysregulation and interactions of gut microbiota regarding IL-10 signalling defects. The understanding of the pathogenesis has informed therapeutic strategies including haematopoietic stem cell transplant and novel biologics such as interleukin 1 receptor antagonist. Optimised transplant regimen and decreased risk of graft versus host disease with gut immunomodulation with vedolizumab might be used to improve transplant outcomes. More recently, gene therapy and gene editing have become treatment options for a range of IEIs, however evidence for IL-10 signalling defects is limited to in vitro and in vivo models. Beyond the Mendelian disorders, IL-10 signalling and neutralizing autoantibodies against IL-10 is relevant to the pathogenesis of polygenic IBD.

1 January 2021
Verified
Conference Paper
Open access
ZYZiqing Ye
Ziqing Ye
JCJiaying Chen
Jiaying Chen
CWChaoyang Wen
Chaoyang Wen
JTJingren Tian
Jingren Tian

3 September 2026 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PYPai-Jui Yeh
Pai-Jui Yeh
JCJames E G Charlesworth
James E G Charlesworth
HTHenry Taylor
Henry Taylor
JAJames Ashton
James Ashton
KNKatrina Nash
Katrina Nash
HUHolm H Uhlig
Holm H Uhlig
Background and aims: Evidence-based, mechanism-guided therapies are urgently needed for treating monogenic inflammatory bowel disease (mIBD). For such rare diseases, mechanistic insight is essential to guide treatment when conventional clinical trials are often not feasible. We aimed to summarize literature-based evidence and to identify knowledge gaps. Methods: We conducted a systematic review of published manuscripts evaluating the therapeutic efficacy in mIBD. We quantified and compared the global therapeutic response score across treatments and conditions. In a subset of conditions, biomarkers of longitudinal therapeutic response were evaluated in comparison to non-monogenic pediatric IBD cohorts. Results: Responses to 35 therapeutics across the 102 known genetic causes of mIBD were evaluated in 241 articles and 669 patients, summarizing 302 gene–drug responses. The efficacy of at least one pharmacological intervention was identified in 61% (n = 62/102) of the mIBD conditions, highlighting a major unmet need for effective medications in many others. Gene- and pathway-specific responses were demonstrated for several therapies, including allogeneic hematopoietic stem cell transplantation, gene therapy, and advanced therapies such as anti-TNF agents, IL-1 inhibitors, mTOR inhibitors, as well as eculizumab in CD55 deficiency, abatacept in CTLA4 deficiency, and the immunometabolic agent empagliflozin in glycogen storage disease type 1b. Conclusions: This study highlights the potential of precision medicine approaches tailored to genetic and pathway-specific mechanisms, while underscoring the urgent need for effective therapies in many monogenic conditions that remain without established treatment options.